Datopotamab deruxtecan with durvalumab and carboplatin for untreated TROP2-positive advanced non-small-cell lung cancer without actionable genomic alterations [ID6522]

• Awaiting development
• Reference number: GID-TA11671
• Expected publication date: TBC